-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
Clinical information, 1s reach
▎Clinical Questions: What are the risk factors for the development of immune thrombocytopenia (ITP) into systemic lupus erythematosus (SLE)? Literature Screenshot ▎ Study Protocol: This study retrospectively looked at 130 patients diagnosed with primary ITP in a tertiary hospital between August 2001 and November 2019 and compared clinical features
based on the development of SLE.
Of the 130 patients with primary ITP, 10 (7.
7%) were later diagnosed with SLE during follow-up [median, 30 months (IQR, 15.
5-105)].
In patients who later develop SLE, skin bleeding, organ bleeding, lymphopenia, anemia, and positive antinuclear antibodies (≥1:160) are more common
than in patients who do not develop SLE.
Multivariate analysis showed that younger age (< 40 years; OR 6.
307, 95%Cl 1.
114~34.
908; P=0.
035), organ hemorrhage (OR, 13.
672, 95% CI 2.
437-76.
689; P=0.
003), and ANA positive (1:160;OR, 6.
638, 95% CI 1.
399-31.
504, P=0.
017) were significantly associated
with the development of SLE.
▎Conclusions and prospects: Young age (< 40 years), organ bleeding, and positive ANA (≥1:160) are risk factors
for SLE in patients with primary ITP.
4.
Follow the column
Subscribe to the column and read a new top issue every day!
Download the Doctor Station App and subscribe anytime, anywhere
